Transforming growth factor (3 (TGF-)3) acts as a potent inhibitor of the growth and functions of lymphoid and hemopoietic progenitor cells. Cell proliferation depends not only on the presence of growth factors, but also on the development of specific receptor-signal transducing complexes . We therefore investigated whether the inhibitory actions ofTGF-# could be mediated by inhibition of growth factor receptors. TGF-(3 inhibited the constitutive level of interleukin 1 receptor (IIr 1R) expression on several murine lymphoid and myeloid progenitor cell lines, as well as IIAR expression induced by interleukin 3 (IIr3) on normal murine and human bone marrow cells. Furthermore, treatment of bone marrow progenitor cells with TGF-O concomitantly inhibited the ability of IIA to promote high proliferative potential (HPP) colony formation as well as blocked IL1-induced IIr2 production by E14 6.1 cells . These findings provide the first evidence that the inhibitory action of TGF-a on the growth and functional activities of hematopoietic and T cells is associated with a reduction in the cell surface receptor expression for IIrl.
Transforminggrowthfactor (3 (TGF-a) is a highly conserved polypeptide, originally characterized by its ability to induce the anchorage-independent growth of NRK 49F fibroblasts in soft agar (1) . Since then, TGF-0 has been shown to be multifunctional in its influence on cell growth. While TGF-a acts as a growth factor for mesenchymal cells, osteoclasts, and Schwann cells, it is also a potent inhibitory signal for a variety of other growth factor-driven biological functions (2) . We have shown that TGF-a is a selective negative regulator of CSF-driven growth ofboth murine and human immature hemopoietic cells (3) (4) . In particular, TGF-IQ inhibits the growth ofprimitive bone marrow progenitors such as the high proliferative potential colony-forming cells (HPP-CFC),t which develop in response to hemopoietin-1 (IL1) plus CSFs (5) . TGF-16 also affects other 11,1-driven biological functions, including collagenase production by synovial ' Abbreviations used in thus paper. DSS, disuccinimidyl suberate; 5-FU, 5-fluorouracil ; HPP-CFC, high proliferative potential colony-forming cells. 737 cells, thymocyte and lymphocyte proliferation, as well as chondrocyte activation (2, (6) (7) (8) .
TGF-0 may inhibit growth factors such as IIA at the level of receptor expression. In this context, high affinity ILiR have been detected on a variety of responsive cells, including fibroblasts, keratinocytes, T cells, B cells, monocytes, and neutrophils (9) (10) (11) (12) . Based on studies of cells transfected with a cDNA encoding for IIr1R, it has been suggested that the density of IL1R can regulate IIr1 action (13) . We therefore tested the effect of TGF-0 on the level of IL1R expressed on murine lymphoid and myeloid progenitor cell lines. We evaluated the effect of TGF-# on IIAR present on several IL3-dependent early myeloid progenitor cell lines . Although IL1R were not significantly detectable on freshly isolated normal murine and human bone marrow cells, treatment with IL3 resulted in a significant upregulation ofreceptor expression. Treatment of these IL3-treated normal hemopoietic progenitor cells, myeloid cell lines, as well as a T cell line with physiological concentration ofTGF-/3 markedly reduced the number ofIIARs and concomitantly resulted in a loss of responsiveness to IILl. These findings suggest that the inhibi-tory action of TGF-(3 may be based on a reduction in cell surface IL1R expression .
Materials and Methods
Animals. BALB/c mice were obtained from the animal facility of the NCI-Frederick Cancer Research Facility (Frederick, MD).
Cytokines. Bovine TGF-O was purified to homogeneity using a previously described procedure (14) . Murine rIIr3 was obtained from the supernatant of COS-7 cells transfected with 11,3 cDNA using a previously described procedure (15) . This supernatant does not contain other CSF activities as measured on factor-dependent cell lines and the endotoxin level was found to be <0 .038 ng/ml. Human 11,3 was obtained from Immunex Corp. (Seattle, WA) and human rIIrla was provided by P. Lomedico from Hoffmann-La Roche, Nutley, NJ .
Cell Lines. The murine 11r3-dependent myeloid hemopoietic cell lines FDC-P1, 32D-c123, and 32D-c113 were derived from longterm bone marrow cultures (16, 17) . NFS-60, NFS-58, and DA-3 were derived from the preleukemic spleens from mice infected with murine leukemia viruses (18) . These cell lines have the characteristics of immature hemopoietic progenitors as determined by morphology, cytochemistry, and cell surface marker expression . The murine myeloid cell line FW311 was derived from fetal liver and the murine myeloid cell line AC-2 was provided by J. Garland. The murine cell line E1,4 6.1, a variant subline of E1,4 thymoma cells (19), was provided by H.R . MacDonald (Ludwig Institute for Cancer Research, Basel, Switzerland) . The murine T cell line LBRM-33-1A4 was purchased from American Type Culture Collection (Rockville, MD).
Preparation of Iodinated ILI a. Human rILla was labeled with tall using chloramineT reagent as described previously (20) . The radiolabeled IIrla had a specific activity that ranged from 1 to 3 x 1011 cpm/mmol . There was no significant loss of biological activity of the radiolabeled 11,1a as measured using the thymocyte co-mitogenic activity assay.
Receptor Binding Assay. After the different treatments, the cell suspension was washed once with cold medium and the cell pellet was treated for 1 min on ice with 50 mM glycine-HCI (pH 3) to remove possible endogenous IL1. Such treatment removes >95% of the bound "I-11,1a . Subsequently, the cells were washed twice with binding medium (RPMI 1% BSA supplemented with 0.1% sodium azide and 10 mM Hepes) and incubated at 4°C with 500 pM tall-labeled human I1r1a in a final volume of 0.2 ml . After 2-3 h incubation at 4°C, cell-bound radioactivity was separated from unbound I'll-11,1a by centrifugation of the sample through a mixture of 1.5 :1 (vol/vol) dibutyl phthalate/bis(2-ethylhexyl)-phthalate (Eastman Kodak Co ., Rochester, NY). Nonspecific binding was determined by incubating the cells with labeled II'Ica in the presence of 50-fold excess of unlabeled ligand .
Affinity Cross-linking. After a 1-h incubation with 125 1-ILl at 4°C, the cells were washed once in cross-linking buffer (PBS, 10 MM MgCl2, pH 8.3) and incubated for 30 min at 4°C with constant rotation in 1 ml of cross-linking buffer containing 100 Ftg disuccinimidyl suberate (DSS ; Pierce Chemical Co ., Rockford, IL). Receptor-bound ligands were cross-linked using 100 fig/ml DSS and rotated at 4°C for 30 min. After two washes in TRIS buffer, 5 x 1(16 cells were solubilized for 30 min at 4°C in lysis buffer (20 mmol/L Tris-HCI, pH 7.4, 50 mmol/liter NaCl, 0.5% NP-40, 0.5% sodium deoxycholate, 4 mmol/liter iodoacetic acid, 5 mmol/liter sodium pyrophosphate, 5 mmol/liter sodium fluoride and 1 mmol/liter PMSF). Lysates were centrifuged at 10,000 g for Proposed Mechanism of Inhibition of Interleukin 1 Action 10 min to remove nuclei and other debris . The protein content of each sample was determined using a commercially available kit (BioRad Protein Assay; BioRad Laboratories, Richmond, CA), and samples containing equal amounts of proteins were run under reducing condition on 7-15% SDS-PAGE . Affinity labeled protein was detected by autoradiography of the dried gels .
HPP Colony Formation. The bone marrow cells were aspirated from the femur of BALB/c mice injected 5 d previously with 5-fluororacil (5-FU; LyphoMed Inc., Rosemont, IL) at 150 mg/kg and plated into a double-layer agar culture system as previously described (21) . After 14 d of incubation, HPP-CFC that represent colonies >0 .5 mm in diameter were scored using a dissecting microscope.
11,2 Production and Assay. E14 6.1 cells were cultured at 2 x 105 cells/ml for 24 h with or without various agents . IL2 activity in the supernatants was quantitated by their ability to support the growth of the IIr2-dependent murine CTLIr2 cells as previously described (22) . Units of 11,2 were analyzed using the PROBIT program.
Results Dose-and Time-dependent Efect of TGRO on NFS-60 Cells. Using 125 1-IIrlCi, we found that three of the seven IL3-dependent myeloid progenitor cell lines tested, namely NFS-60, NFS-58, and AC-2, were positive for IIAR expression (ratio of specific/nonspecific binding, >1) ( Table 1) . We used the I1r1R+ cell line NFS-60 to study the effect of TGF-/3 on IIAR expression in detail. When NFS-60 cells maintained in IL3 were treated for 24 h with increasing concentrations of TGF-a, we observed a dose-dependent reduction in IL 1R Table 1 .
IL-1R Expression on Murine Hemopoietic Progenitor Cell Lines
Factor-dependent cell lines were maintained in RPMI medium containing 20% WEHI-3 conditioned medium . t The specific binding was determined by subtracting the number of counts per minute bound in the presence of 50-fold excess IL-la. Each point represent the mean ± SEM of two or more determinations. In our assay, the ratio of specific/nonspecific binding >1 was statistically shown to reflect the presence of a detectable and measurable number of receptors. expression with an ED5o of 0.2 ng/ml (10-11 M) and a maximal effect at 20 ng/ml ( Fig. 1 A) , concentrations that are within the physiological range (2) . Kinetic studies revealed that >50% inhibition of TGF-,3 action occurred within 6 h and maximal effect (>90%) was observed at 24 h ( Fig. 1 B) .
The inhibitory effect of TGF-(3 was not due to a direct competition of TGF-(3 for IL I binding sites on the cell surface.
As much as 250 ng/ml (10-e M) of unlabeled TGF-# in our binding assay did not complete with the binding of radiolabeled ILla (data not shown) . Moreover, high cell viability was maintained as determined by trypan blue exclusion .
Selective Effect of TGF-a on Cell Surface Protein Expression . To determine whether the inhibition of IL1R expression by TGF-((3 reflects a general decrease in cell surface protein, we tested the effect of TGF-a on a variety of murine myeloid cell surface antigens. Data from cytofluorometric analysis indicated that the addition of TGF-i0 to NFS-60 cells under culture conditions resulting in maximal inhibition of IIr1R (24 h, 20 ng/ml) did not affect the expression of any of the five cell surface antigens tested (data not shown) . These included Thy-1.2 (T cells and progenitor cells), Ly-5 (pan leukocyte), Mac-1 (granulocytes and macrophages), RBC-8C5 (granulocytes), and LY17 (Fc receptor) . Equilibrium Binding of 115 1-ILI a to NFS-60 Cells. To determine whether the reduction in ILI binding was due to a decrease in the number of ILIR, NFS-60 cells maintained in IL3 were incubated for 24 h with or without TGF-0. The cells were washed, treated with glycine-HCI, and then incubated at 4°C with increasing concentrations of 125 1-ILla. A plot ofspecific counts bound, as a function of radio ligand concentration (Fig. 2 A) , indicated that binding was dose dependent and saturable . Pretreatment with TGF-a almost completely abolished the subsequent specific binding of labeled ILI without any noticeable effect on the nonspecific binding component (Fig. 2 B) . Data from Scatchard analysis ( (Fig. 3) . These data suggested that TGF-((3 was not inducing the production of ILI by the myeloid cells. LPS, a potent ILI induer, also failed to induce the production of detectable ILI binding activity by NFS-60 cells. Additionally, TGF-a did not change the level or rate of ILIR internalization by labeled ILla (data not shown) . Affinity Cross-linking of 125 1-IL-1 a to Control and TGF-0-treated Cells. Affinity labeling of the hemopoietic progenitor cell lines NFS-60 and AC-2, which were maintained in IL3, with 125 1-IL1 followed by cross-linking revealed one sharp band of -65-70 kD (Fig. 4) . This band was ablated by addition of 50-fold excess of unlabeled IL1, and thus represents an ILI binding protein on NFS-60 and AC-2 cells. Pretreatment of the cells for 24 h with TGF-i O resulted in a marked inhibition of the 65-70-kD IL I binding protein on NFS-60 and AC-2 cells (Fig. 4) .
Induction of IL1R Expression on Murine and Human Bone
Marrow Cells by 11,3 . Using 125 1-IL-la, we found that normal unstimulated murine and human bone marrow cells do not show significant binding of radiolabeled ILl. However, 24-48 h incubation with IL3, a T lymphocyte derived growth factor for hemopoietic progenitor cells (24), resulted in a significant increase in ILI binding (Table 2) . Cross-linking data indicated that murine bone marrow cells displayed a faint but identical band of 65-70 kD, whose in- Effect ofTGRO on ILIR Expression~a T Cell Line. To determine whether the effect of TGF-on progenitor cells could be applied to other cell types, we performed similar cross-linking experiments using EL4, a murine thymoma cell line. As previously reported, labeled II*1 binds predominantly to a 78-85-kD protein on this cell type (Fig. 4) (25, 26) . Twenty-four hours ofpretreatment with TGF-0 also inhibited the majority of ILl binding protein on the T cell line (Fig. 4) .
Biological Effect of TGF--S on ILI-induced Biological Activities. We next evaluated the relationship of the inhibition of IIAR expression on bone marrow and E14 cells to the biological effects of ILI . First, using the soft agar colony formation assay and IIr3 as a co-stimulator, we observed that the addition of TGF-0 abrogated the effect of IM on HPP-CFC colony formation (Table 2 ). These results show that TGF-0 inhibits the effect of IM on the growth of progenitor enriched 5-FU-treated murine bone marrow cells along with the reduction of IL1R expression. We also evaluated the effect of TGF-0 on IL-1-induced 11,2 production in the murine cell line, EL4 6 .1 C10. As already reported, this T cell line produces a detectable amount of 11,2 when stimulated with IL1 alone (27) . Our data indicates that pretreatment with TGF-0 for 8-12 h inhibited the ability of IL1 alone or in combination with calcium ionophore to induce 11,2 production by E1,4 6.1 cells (Table 3) .
Discussion
Several laboratories have demonstrated that TGF-fi negatively regulates the growth of murine and human hematopoietic cells in vitro and in vivo (3) (4) (5) (28) (29) (30) . In addition, we have shown that TGF-0 selectively inhibits the growth of primitive hematopoietic progenitors (CFU, granulocytes
[CPU-GEMM] and HPP), while more committed progenitors (CFU-G, CFU-M, and CFU-E) are insensitive (3, 4) . IIA is known to be biochemically identical to hemopoietin-1 and has positive effects on hemopoiesis in promoting the growth and survival of early progenitor cells (31) (32) . Since HPP progenitor cells require IM and CSFs to proliferate and differentiate in vitro and are inhibited by TGF-A (5), we asked whether one potential mechanism of TGF-0 action might be at the level ofILl receptor expression. Using cross-linking technology we found that IIAR expression is markedly inhibited on I1,3-treated and 5-FU-treated bone marrow cells. However, the expression of IL1R in normal and 5-FU-treated bone marrow is not sufficient to allow accurate equilibrium binding studies. Thus, we identified several IL1R+ murine hematopoietic progenitor cell lines representative of immature hematopoietic cells, blocked in differentiation. Treatment of these progenitor cell lines with TGF-a markedly inhibited IL1R expression without a general inhibition of cell surface protein expression, suggesting that one mechanism of growth inhibition might be related to the decrease in the number of cell surface IL1R .
Since ILA has been reported to inhibit the expression of Table 2 . IL-1R Expression on Murine and Human " Murine bone marrow cells were obtained as described in Material and Methods. The cells were incubated 24 h with or without murine IL-1 used at 20 ng/ml. Human bone marrow cells were obtained from healthy donors and the mononuclear cells were isolated by centrifugation on Ficoll-Hypaque gradient . The cells were incubated 48 h in the presence or absence of 10 ng/ml human IL-3 . t The specific binding and ratio was determined as described at the legend of Table 1. 741 Dubois et al.
receptors for ILA through the internalization of the receptorligand complex (33), we tested whether induction of ILl by TGF-0 was responsible for the reduction in IL1R . The supernatant from TGF-/3-treated NFS-60 cells failed to compete for radiolabeled ILl in binding assays. Thus, in contrast to data reported for mature monocytes (23), the early myeloid cell lines do not produce IL1 or "IL1-like" binding activities in response to TGF-/3 . These data suggest that TGF-0 acts 4irectly to inhibit the expression of IL 1R. Whether TGF-0 inhibits ILlR expression at the level of transcription will be investigated using a cDNA probe for IL1R (25). Two different classes of antigenically and biochemically distinct ILA receptors have been identified by different laboratories (34) (35) . By affinity cross-linking, the molecular weight of the TCR (EL4) is 87 kD, whereas the B cell receptor (70Z/3 cells) is 66 kD (35) . The presence of a B cell-type IL1R has also been reported on a mature bone marrow-derived granulocytic population (33) . In our experiments, affinity labeling and cross-linking showed that TGF-0 inhibited a 65-70-kD ILloi binding protein on freshly aspirated progenitor cells (5-FU-treated) and on the progenitor cell lines. Based on the molecular weight of the ILiR present on progenitor cells, our data suggest that these progenitor cells expressed the B cell-type receptor. In addition, TGF-0 also inhibited the 80-85-kD protein expressed on T cells. Thus, TGF-0 inhibits both classes of IL1R.
On normal bone marrow cells, IL-3 treatment upregulates two different molecular mass IL1 binding proteins (65-70 kD, 180 kD), both of which are inhibitable when TGF-0 is present in the assay. These results indicate that TGF-0 can inhibit the induction by IL3 of IL1R in vitro. Recent data from our laboratory indicate that TGF-0 can also similarly inhibit IL1R expression induced in vivo on bone marrow cells (manuscript in preparation), which supports the pro- The HPP colony formation assay was performed as described in Material and Methods. For this assay, 20 ng/ml of TGF-/3 was added to the cultures, human recombinant IL-la was used at the indicated doses and murine recombinant IL-3 was used at 20 ng/ml. t The IL-2 production assay was performed as previously described (21) using EL-4 6.1 C10 cells, an IL-1-responsive murine thyoma cell line . For this assay, human IL-la was used at 30 pg/ml, and calcium ionophore (A23187) was used at 5 x 10 -6 M. Units of IL-2 were analyzed using the PROBIT program.
posed role for TGF-0 as a negative regulator of hemopoietic cell growth in vivo. In this regard, the inhibition of IL1-dependent hematopoiesis by TGF-0 may ultimately result in a depletion of macrophages and other marrow-derived inflammatory cells, since we find (unpublished observation) that the bone marrow ofTGF-/3-treated mice becomes hypoplastic. It has been postulated that the mechanism regulating IL1 responsiveness is related to IL1R expression. This is supported by experiments showing that IL1 induction ofprostaglandins and CSFs by CHO cells that express low numbers of IL1R is increased by transfection with cDNA encoding for IL1R (13) . Additionally, treatment offibroblasts with platelet-derived growth factor increased the number of IL1R together with the capacity of the cells to proliferate in response to ILl (36) .
The results presented here demonstrate that TGF-/3 inhibits HPP colony formation together with an inhibition of ILlR expression. Since HPP cells also require IL3 and CSF-1 in addition to RA for continued growth, it is possible that the growth inhibitory effect of TGF-0 may also involve inhibition of receptors for the CSFs. In addition, it is possible that the downregulation of IL1R occurs secondarily to inhibition of cell growth/colony formation. However, we consider this unlikely since 50% ofthe IL1R downmodulation occurs within 6-8 h, reaching a maximum at 24 h which precedes any observed effect on cell growth (usually detectable within 3-5 d). In fact, recent data from our laboratory indicate that expression of CSF receptors was also inhibited by TGF-0 (manuscript in preparation) . Thus the diminution of cell surface ILlR on progenitor cells represents a model for the mechanism of growth inhibition by TGF-0 that could possibly be extended to other cell surface receptors .
IL2 production by the T cell line EL4 6.1 induced by IL1 alone is inhibited by pretreatment with TGF-(3, which argues for a direct relationship between IL1R inhibition and T cell function. Thus, TGF-0 may block IL1-driven T cell activation, by inhibiting cell surface IL1R expression. Our findings that TGF-0 inhibits IL1R expression on T cells provides a basis for the proposed immunosuppressive role for this cytokine (37) that can block IA-driven T cell-dependent B cell reactions and thymocyte proliferation .
TGF-0 has been proposed to be a pro-inflammatory agent, based on its ability to chemoattract peripheral monocytes and to induce IL1 mRNA expression (23). On the other hand, TGF-0 reduces the production of H202 by already activated macrophages (38) . Even though injections ofTGF-0 induce a mononuclear cell infiltrate and edema, TGF-a, unlike IL1, does not induce any erythema as in classical inflammation. Our data can reconcile these apparently contradictory observations since the inhibition of IL1R expression by TGF-0 renders the cells unresponsive to IL1 thus providing a mechanism by which TGF-0 minimizes inflammatory responses and promotes the repair process.
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